Urol. praxi, 2014; 15(5): 208-210

Immunotherapy in prostate cancer

MUDr.Kateřina Kubáčková
Onkologická klinika 2. LF UK a FN Motol, Praha

The immunotherapy based on progress in tumour immunology became a part of intensive research as a novel strategy in cancer treatment.

Sipuleucel-T is the first and only medicinal product approved by the regulatory agencies in USA and Europe for the treatment of

asymptomatic or minimal symptomatic castrate- refractory prostate cancer. It represents the first product of autollogous cell therapy.

This article gives a brief overview about new approaches in the cancer immunotherapy in clinical development.

Keywords: prostate carcinoma, tumour immunology, immunotherapy, cancer vaccines

Published: December 16, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubáčková K. Immunotherapy in prostate cancer. Urol. praxi. 2014;15(5):208-210.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coulie PG, Eynde BJV, Bruggen P, et al. Tumor antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Clin Oncol 2014; 14: 135-146. Go to original source...
    2. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Clin Oncol 2012; 12: 860-862. Go to original source... Go to PubMed...
    3. Mc Neel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patiens with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012; 61: 1137-1147. Go to original source... Go to PubMed...
    4. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and aktivity od anti-PD-L1 antibody in patiens with advanced cancer. N Engl J Med 2012; 366: 2455-2465. Go to original source... Go to PubMed...
    5. Tang PA, Heng DYC. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013; 15: 98-104. Go to original source... Go to PubMed...
    6. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8: 711-719. Go to original source... Go to PubMed...
    7. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy dones of age. Nat Rev Clin Oncol 2011; 480: 480-489. Go to original source...
    8. Burch PA, Breen JK, Buckner JC, et al. Primary tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-2182.
    9. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy foro castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422. Go to original source... Go to PubMed...
    10. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62: 137-147. Go to original source... Go to PubMed...
    11. Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-1397. Go to original source... Go to PubMed...
    12. Fong L, Weinberg V, Chan SE, et al. Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment/abstract 2564/. ASCO annual meeting abstracts. Accesed september 10, 2013. Go to original source...
    13. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105. Go to original source... Go to PubMed...
    14. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 663-674. Go to original source... Go to PubMed...
    15. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5: 1738-1744.
    16. Higano C, Saad F, Somer B, et al. A phase III trial od GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC)/abstract LBA150/. Presented at the Genitourinary Cancers Symposium. Orlando, Florida, February 26-28 2009.
    17. Cheng ML, Fong L. Beyond sipuleucel-T: Immune approaches to treating prostate cancer. Science, 2014; doi: 10.1007/s11864-013-0267-z. Go to original source... Go to PubMed...
    18. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Science, 2014; doi: 10.1007/s10555-013-9479-8. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.